SPECTAlung: Screening Patients With Thoracic Tumors for Efficient Clinical Trial Access

NCT02214134 | Completed DMC

• 1 other identifier: EORTC-1335-LCG-PBG
• Study Type: observational
• Target: 539
• Locations: 9 countries
• Sites: 18

Brief Summary

SPECTAlung is a program aiming at screening patients with thoracic tumors to identify the molecular characteristics of their disease. The thoracic tumors include lung cancer, malignant pleural mesothelioma, thymoma or thymic carcinoma at any stage. Once the molecular characteristics are identified, there might be the possibility to offer these patients access to targeted clinical trials.

Conditions

Any Stage of Lung Cancer (Any Histotype); Any Stage of Malignant Pleural Mesothelioma; Any Stage of Any Thymic Malignancy

Keywords

Lung cancer; Malignant pleural mesothelioma; Thymic malignancy; Biomarkers; Screening

Outcome Measures

Primary Outcomes (1)

• Number of patients with thoracic malignancy (lung cancer, MPM and thymic malignancies) screened and efficiently allocated to biomarker-driven clinical trials.

  5 years

Secondary Outcomes (2)

• Number of patients for whom the description of the biomarkers and correlation to clinical/pathological characteristics can be performed.

  5 years

• Number of exploratory/future research projects developped

  5 years

Study Arms (3)

Lung cancer

Patients with diagnosis of lung cancer at any stage

Genetic: Tumour markers testing

Malignant pleural mesothelioma

Patients with diagnosis of malignant pleural mesothelioma at any stage

Genetic: Tumour markers testing

Thymic malignancy

Patients with diagnosis of thymic malignancy at any stage

Genetic: Tumour markers testing

Interventions

Tumour markers testing GENETIC

Lung cancer; Malignant pleural mesothelioma; Thymic malignancy

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with pathologically confirmed lung cancer, MPM, thymoma or thymic carcinoma at any stage.

You may qualify if:

• Pathologically confirmed lung cancer, MPM, thymoma or thymic carcinoma at any stage;
• Centrally performed confirmation of tumor tissue adequacy in terms of quality/ quantity for central screening;
• Age ≥ 18 years;
• At least three months life-expectancy;
• Written informed consent according to ICH/GCP and national/local regulations.

You may not qualify if:

• Any active malignancy, except pT1-2 prostatic cancer Gleason score \< 6, non melanomatous skin cancer or carcinoma in situ of the cervix, in the 5 years before study entry;
• Active hepatitis B/C or HIV;
• Any secondary malignancy;

Sponsors & Collaborators

• European Organisation for Research and Treatment of Cancer - EORTC: lead
• ETOP IBCSG Partners Foundation: collaborator

Study Sites (18)

Hopitaux Universitaires Bordet-Erasme - Institut Jules Bordet

Brussels, 1000, Belgium

Location

Universitair Ziekenhuis Antwerpen

Edegem, Belgium

Location

U.Z. Leuven - Campus Gasthuisberg

Leuven, 3000, Belgium

Location

CHU de Lyon - Hopital Louis Pradel

Lyon, 69394, France

Location

Assistance Publique - Hopitaux de Marseille - Hopital Nord

Marseille, 13015, France

Location

CHU Toulouse - Hopital Larrey

Toulouse, 31059, France

Location

Gustave Roussy Cancer Campus

Villejuif, 94805, France

Location

St. James's Hospital

Dublin, Ireland

Location

Ospedale S. Luigi Gonzaga - Universita Di Torino

Torino, 10043, Italy

Location

Medical University Of Gdansk

Gdansk, 80211, Poland

Location

University Clinic Golnik

Golnik, 4204, Slovenia

Location

Hospital General Vall D'Hebron

Barcelona, 08035, Spain

Location

Hospital Universitario 12 De Octubre

Madrid, ES 28041, Spain

Location

Centre Hospitalier Universitaire Vaudois - Lausanne

Lausanne, CH 1011, Switzerland

Location

Centre Hospitalier Universitaire Vaudois - Lausanne

Lausanne, CH1011, Switzerland

Location

Royal Marsden Hospital - Kingston Hospital

Kingston upon Thames, KT2 7QB, United Kingdom

Location

Royal Marsden Hospital - Chelsea, London

London, SW3 6JJ, United Kingdom

Location

Royal Marsden Hospital - Sutton, Surrey

Sutton, SM2 5PT, United Kingdom

Location

Biospecimen

Retention: SAMPLES WITH DNA

FFPE blocks of tumour tissue Blood samples Pleural effusion samples

MeSH Terms

Conditions

Lung Neoplasms; Mesothelioma, Malignant

Condition Hierarchy (Ancestors)

Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases; Mesothelioma; Adenoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms, Mesothelial; Pleural Neoplasms

Study Officials

• Benjamin Besse, MD, PhD

  Gustave Roussy, Cancer Campus, Grand Paris

  STUDY CHAIR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 5 Years
• Sponsor Type: NETWORK
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 7, 2014
• First Posted: August 12, 2014
• Study Start: May 22, 2015
• Primary Completion: October 22, 2020
• Study Completion: May 12, 2021
• Last Updated: August 17, 2025

Record last verified: 2025-08

Locations

ES (2); IT (1); SL (1); IE (1); FR (4); PL (1); CH (2); BE (3); GB (3)